| /s/ Alain Guimond PhD |   |
|-----------------------|--------|

----

| BETWEEN: | 7810962 Canada Inc., a corporation duly incorporated under the laws of Canada and having its principal place of business at 5320 13e Avenue, Montréal, Québec, H1X 2X8; |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (hereinafter referred to as “7810962”) |
|--------|----------------------------------------------------|

| AND: | RedHill Biopharma Ltd., a corporation duly incorporated under the laws of Israel and having its principal place of business at 21 Ha’arba’a Street, Tel Aviv 64739, Israel; |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| BETWEEN: | [****], a corporation duly incorporated under the laws of Canada and having its principal place of business at [****]; |
|----------|------------------------------------------------------------------------------------------------------------------------|

|   | (hereinafter referred to as “[****]”) |
|--------|---------------------------------------------------|

| AND | 7810962 Canada Inc., a corporation duly incorporated under the laws of Canada and having its principal place of business at 5320 13e Avenue, Montréal, Québec, H1X 2X8; |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (hereinafter referred to as the “Client”) |
|--------|-------------------------------------------------------|

|   | ([****] and the Client are at times referred to individually as the “Party” and collectively the “Parties”) |
|--------|-------------------------------------------------------------------------------------------------------------------------------------|

| A.   | The Client and [****] entered into a Master Service Agreement dated July 5, 2011 (the “MSA”). |
|----------------|-----------------------------------------------------------------------------------------------------------|

| B.   | The Parties hereto wish to describe the services to be performed in connection with the MSA, subject to the terms and conditions set forth herein and in the MSA. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C.   | Unless the context otherwise requires, all capitalized terms used in this Service Agreement shall have the meanings attributed to them in the MSA. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.   | INTERPRETATION |
|----------------|----------------|

| 2.   | DESCRIPTION AND DELIVERABLES |
|----------------|------------------------------|

| 2.1-   | [****] study |
|------------------|--------------|

----

| Storage Condition | Time point(Day) |
|-------------------|-----------------|
| Initial           | [****]          | [****] |
| [****]            | [****]          | [****] | [****] |
| [****]            | [****]          | [****] |

|   | Cost: | [****] |
|--------|-------|--------|

| * | Cost based on the analysis of the two APIs (i.e., [****] and [****]) for [****] samples ([****] X 4 conditions ([****] [****] [****] and [****]) X 3 time points) at $ [****]/sample AND [****] analytical set-ups ([****] time points [****]/ time point) at $[****]/ set-up. |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2-   | Formulation development |
|------------------|-------------------------|

| · | [****] ([****][****] and [****]), and; |
|--------|----------------------------------------|

| · | [****] ([****] [****] and [****]), and; |
|--------|-----------------------------------------|

| · | [****] ([****][****] and [****]). |
|--------|-----------------------------------|

| 2.3-   | Analytical method development and analysis |
|------------------|--------------------------------------------|

|  Cost: [****] |
|-------------------------|

| 2.4-   | Stability of prototype formulations |
|------------------|-------------------------------------|

| · | Justification of up to [****] for non-GMP stability study; |
|--------|------------------------------------------------------------|

----

| · | Manufacturing and packaging of up to [****]; |
|--------|----------------------------------------------|

| · | Sample incubation under the following conditions of temperature and humidity: [****]; |
|--------|---------------------------------------------------------------------------------------|

| · | Justification of finished product specifications; |
|--------|---------------------------------------------------|

| · | Physico-chemical characterization at each of the following conditions (Includes: Appearance, Assay*, Degradation Products*, Dissolution* and Water content). |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Storage Condition | Time point ([****]) |
|-------------------|---------------------|
| Initial           | [****]              | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]              | [****] | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]              | [****] | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]              | [****] | [****] | [****] | [****] | [****] | [****] |

| Cost: | $32,016** |
|-------|-----------|

| * | On the [****] APIs. |
|---|---------------------|

| ** | The decision of testing the highest and lowest strength only  and extrapolating the stability results to the middle dosage strength (bracketing) will be taken by the Client. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| *** | Based on [****]/ sample using a bracketing study design. |
|-----|----------------------------------------------------------|

----

| 2.5-   | Manufacturing of the Phase III Clinical Trial Material (CTM) |
|------------------|--------------------------------------------------------------|

| 2.5 a)  | GMP material storage and handling |
|--------------|-----------------------------------|

|   | Cost: | $1,455* |
|--------|-------|---------|

| * | The cost includes: |
|---|--------------------|

| · | the reception of one lot of each of the three GMP APIs (i.e., documentation review, material registration in [****] inventory, and material sampling following GMP requirements) (If API lot is in more than one container then the sampling and ID testing of each of the additional containers will be considered Extra Work at [****]/additional container), |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | the ID testing for the release of the three lots of APIs (one for each API) using validated methods. (Client will ship the GMP APIs to [****] with the complete certificate of analysis otherwise Extra Work may be required to release the GMP APIs.), |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | the GMP warehousing of the API and the drug product until completion of the study. If the material needs to be stored for a longer period of time then the storage cost will be [****]. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | the shipping document preparation and shipment of material. |
|--------|-------------------------------------------------------------|

| · | The purchase of the analytical reference materials to be used as a standard, if needed, reference impurities (synthesis by-products, degradation products, metabolites) of known purity estimated cost is [****]. Subject to pre-approval in writing by the Client of the purchasing of the materials, [****] will order the materials. The cost of the materials and any related costs (e.g. transportation or custom fees) will be charged at cost to Client and will not exceed a cap of [****]. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Subject to pre-approval in writing by the Client, repackaging of material (if required) as well as the shipping cost and custom fees, if any, provided not exceeding a cap of [****]. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.5 b)  | GMP Manufacturing, packaging and labelling |
|--------------|--------------------------------------------|

| a)   | Recommendation and justification of specific finished product release, in process testing, stability as well as excipients and packaging components specifications, |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| b)   | Formulation and process information for the redaction of Master Manufacturing File (MMF) |
|----------------|------------------------------------------------------------------------------------------|

| c)   | The CTM will be manufactured and packaged/labeled in [****] bottles with induction seal at [****] units per bottle: |
|----------------|---------------------------------------------------------------------------------------------------------------------|

| · | [****] – [****] units*; |
|--------|-------------------------------|

| · | [****] – [****] units*; |
|--------|-------------------------------|

| · | [****] – [****] units*; |
|--------|-------------------------------|

| · | RHB-105 placebo – [****] units*. |
|--------|----------------------------------------|

| d)   | Monitoring and supervision of the manufacturing, packaging and analytical operations. |
|----------------|---------------------------------------------------------------------------------------|

| Cost: | $136,875**, *** |
|-------|-----------------|

| * | Includes [****] capsules of [****] for the CTM [****] study: [****] bottles of [****] capsules/ time point/ condition and [****] bottles of [****] capsules for [****] (to be done [****]). It includes also [****] of placebo. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ** | Based on the hypothesis that the [****]. If the [****] then, subject to pre-approval in writing by the Client, the following CTM will be [****] at an additional cost of [****]. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | [****] - [****] units; |
|--------|------------------------|

| · | [****] - [****] units; |
|--------|------------------------|

| · | [****] - [****] units; |
|--------|------------------------|

| · | RHB-105 Placebo [****] units. |
|--------|-------------------------------|

|   | This same additional cost of [****] will apply in case the decision is taken to [****] detailed in [****]. |
|--------|------------------------------------------------------------------------------------------------------------|

| *** | If the manufacture of the placebo units is not needed then cost will be reduced by [****]. |
|-----|--------------------------------------------------------------------------------------------|

| 2.5 c)  | Analytical method validation |
|--------------|------------------------------|

| Cost: | $75,100* |
|-------|----------|

| * | Includes analytical method validation of assay and content uniformity, related substances, and dissolution for the three strengths as well as for cleaning. If required and pre-approved in writing by the Client, the analytical method validation for the microbial limit will be done at an additional cost of [****]. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.5 d)  | Release testing and cleaning verification |
|--------------|-------------------------------------------|

| · | [****]*, |
|--------|----------|

| · | [****]*, |
|--------|----------|

| · | [****],** [****]**, |
|--------|---------------------|

| · | [****]**, |
|--------|-----------|

| · | [****]***, |
|--------|------------|

| · | [****]****. |
|--------|-------------|

| Cost: | $23,383***** |
|-------|--------------|

| * | Analyse done also on placebo. |
|---|-------------------------------|

| ** | For the [****] APIs. |
|----|----------------------|

| *** | A dissolution test is [****]. |
|-----|-------------------------------|

| **** | Done only if requested by the Client. |
|------|---------------------------------------|

| ***** | Cost includes the release of one lot of each of the three strengths as well as one lot of placebo. If required and pre-approved in writing by the Client, the analysis of microbiolgy will be done at an extra cost of [****]. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.5 a)  | Stability of the CTM |
|--------------|----------------------|

| Storage Condition | Time point [****] |
|-------------------|-------------------|
| Initial           | [****]            | [****] | [****] | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]            | [****] | [****] | [****] | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]            | [****] | [****] | [****] | [****] | [****] | [****] | [****] | [****] |
| [****]            | [****]            | [****] | [****] | [****] | [****] | [****] | [****] | [****] | [****] |

|   | X: Sample to be analyzed for appearance, assay, related substances, dissolution* and water content. |
|--------|-----------------------------------------------------------------------------------------------------|

|   | Cost: | $88,800*** |
|--------|-------|------------|

| * | A dissolution test is a single time point and six vessels/ time point. |
|---|------------------------------------------------------------------------|

| ** | The decision of testing only the highest and lowest dose strength and extrapolating the stability results to the [****] will be taken by the Client. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------|

| *** | Based on the analysis of [****] using a bracketing study design.  The analyses of placebos [****] will be done only if requested and pre-approved in writing by the Client and they are not included in the cost above. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.6-   | Reports and submission documentation |
|------------------|--------------------------------------|

| · | Telephone meetings will be held on a weekly basis on a specific day of the week and at a specific time agreed to by the Parties. |
|--------|----------------------------------------------------------------------------------------------------------------------------------|

| · | Client or Client’s representative meeting in [****] facility will be held at Client’s request. |
|--------|------------------------------------------------------------------------------------------------------------|

| · | [****] facility and quality audit by Client’s or Client’s representative will be held at Client’s request. |
|--------|------------------------------------------------------------------------------------------------------------------------------|

| · | Progress reports will be provided on a weekly basis. |
|--------|------------------------------------------------------|

| · | Item reports will be provided as they are completed. |
|--------|------------------------------------------------------|

| · | The final development report(s) will include the followings: |
|--------|--------------------------------------------------------------|

| o   | The methodology and the results; |
|---------------|----------------------------------|

| o   | The finished products release & stability specifications, in process specifications and specific APIs, excipients and packaging specifications. Specifications will be provided, for US submissions; |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| o   | The final formulation and manufacturing process. |
|---------------|--------------------------------------------------|

| · | A final manufacturing process report will be provided at the end of the study. It will include all the necessary submission documents related to manufacturing and packaging which include (but are not limited to): |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| o   | The finished products release & stability certificate of analysis. |
|---------------|------------------------------------------------------------------------|

| o   | In process results. |
|---------------|---------------------|

| o   | QA Reviewed and audited Manufacturing and Packaging Documents. |
|---------------|----------------------------------------------------------------|

| o   | Certificate of cGMP compliance. |
|---------------|---------------------------------|

| o   | Certificate of analysis of raw materials and packaging components. |
|---------------|--------------------------------------------------------------------|

| o   | Any atypical report or Out-of-Specification reports. |
|---------------|------------------------------------------------------|

| * | Based on a value of[****] of the sub-total of all invoices before taxes. If [****], [****] and [****] are selected for the manufacturing of the CTM, then the cost for section 2.6 will be $[****]. |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | GENERAL PROJECT TIMELINES |
|----------------|---------------------------|

|   | [****] |
|--------|--------|

----

| 4.   | STARTING DATE AND COMPLETION |
|----------------|------------------------------|

| 4.1   | Notwithstanding the date of signature of this Service Agreement, [****] shall start the performance of the Services within ten (10) business days after [****] satisfaction of the following: |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.1   | signature by the Client of this Service Agreement; and |
|-------------------|--------------------------------------------------------|

| 4.1.2   | complete delivery by the Client of all of the items mentioned at sub-sections 6.1 to 6.3 inclusive of section 6 hereof entitled “REQUIREMENTS”. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2   | This Service Agreement shall be deemed completed upon full delivery of the Services by [****] and receipt by [****] of the final and last payment for the Services. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | ASSUMPTIONS |
|----------------|-------------|

| 5.1   | The target formulation of RHB-105 will be the following drug products with the three actives (The ‘APIs’) combined with pharmacopeia excipients and compressed or encapsulated: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | [****] with [****], [****], and [****] |
|--------|----------------------------------------|

| · | [****] with [****], [****], and [****] |
|--------|----------------------------------------|

| · | [****] with [****], [****], and [****] |
|--------|----------------------------------------|

| · | [****] with [****], [****], and [****] |
|--------|----------------------------------------|

| · | [****] with [****], [****], and [****] |
|--------|----------------------------------------|

| · | [****] with [****],[****], and [****] |
|--------|---------------------------------------|

| 5.2   | The best efforts will be made by [****] to reduce the project timelines. |
|-----------------|--------------------------------------------------------------------------|

| 5.3   | When decisions need to be taken to move forward in the project at the decision time point, the Client will provide its decision in writing to [****] within a period of 5 days. Otherwise the project may be delayed. [****] will develop a final timeline for this project and all deviations will be immediately reported to the Client. [****] will make its best efforts to correct all deviations in order to maintain the project timelines. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.4   | All APIs will be sourced by Client. Non-GMP material can be used in the development phase however it should be of identical quality as the GMP material that would be use in the GMP manufacturing. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.   | REQUIREMENTS |
|----------------|--------------|

| 6.1   | All the available information on APIs (e.g.: interactions, stability, impurities). |
|-----------------|------------------------------------------------------------------------------------|

| 6.2   | The APIs, reference materials to be used as a standard, reference impurities (synthesis by-products, degradation products, metabolites) of known purity, certificate of analysis and APIs’ MSDS. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3   |  For the formulation development, a minimum quantity of [****] of [****] [****] of [****] and [****] of [****] as well as sufficient quantities of related substances (standards, references, impurities) for each APIs. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.4   | For cGMP manufacturing of CTM, a minimum quantity of [****] of [****] [****] of [****] and [****] of [****] will be required. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

| 7.   | COST AND PAYMENTS |
|----------------|-------------------|

| 7.1   | The cost of the Services is up to $[****] ($[****] with a rebate of $[****])or up to $[****] if the placebo manufacture are not required (section 2.5 b)). Any amount exceeding a total of $[****] requires a pre-approval in writing by the Client. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2 | The Client shall pay to [****] the following installments in United-States currency ($USD): |
|-----|---------------------------------------------------------------------------------------------|

| 7.2.1   | $[****] upon signature of this formulation development project Agreement; and |
|-------------------|-------------------------------------------------------------------------------|

| 7.2.2   | $[****] at the initiation of the stability study for the prototypes; and |
|-------------------|--------------------------------------------------------------------------|

| 7.2.3   | $[****] ($[****] if placebo manufacture are not required) at the initiation of the CTM manufacturing; and |
|-------------------|-----------------------------------------------------------------------------------------------------------|

| 7.2.4   | $[****] ($[****] if placebo manufacture are not required) at the completion of the CTM manufacturing report issued by [****]; and |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 7.2.5   | $[****] at the acceptance of the final CTM manufacturing process report by the Client in writing as a final report; and |
|-------------------|-------------------------------------------------------------------------------------------------------------------------|

| 7.2.6   | Stability studies (prototypes [****] (as per section 2.4) and CTM [****] as per section 2.5 e) to be invoiced as per the following schedule of payment. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Expected date that material will be introduced in stability chamber | [****]            |
|---------------------------------------------------------------------|-------------------|
|                                                                | Time Point [****] |
| 0                                                                   | 1                 |
| Date of pull out                                                    | [****]            | [****] |
| Date Results available                                              | [****]            | [****] |
| Month of invoice                                                    | [****]            | [****] |
| Amount to be invoiced                                               | [****]            | [****] |

| Expected date that material will be introduced in stability chamber | [****]            |
|---------------------------------------------------------------------|-------------------|
|                                                                | Time Point [****] |
| 1                                                                   | 2                 |
| Date of pull out                                                    | [****]            | [****] |
| Date Results available                                              | [****]            | [****] |
| Month of invoice                                                    | [****]            | [****] |
| Amount to be invoiced                                               | [****]            | [****] |
|                                                                | Time Point [****] |
| [****]                                                              | [****]            |
| Date of pull out                                                    | [****]            | [****] |
| Date Results available                                              | [****]            | [****] |
| Month of invoice                                                    | [****]            | [****] |
| Amount to be invoiced                                               | [****]            | [****] |
|                                                                | Time Point [****] |
| [****]                                                              | [****]            |
| Date of pull out                                                    | [****]            | [****] |
| Date Results available                                              | [****]            | [****] |
| Month of invoice                                                    | [****]2           | [****] |
| Amount to be invoiced                                               | [****]            | [****] |
|                                                                | Time Point [****] |
| [****]                                                              | [****]            |
| Date of pull out                                                    | [****]            | [****] |
| Date Results available                                              | [****]            | [****] |
| Month of invoice                                                    | [****]            | [****] |
| Amount to be invoiced                                               | [****]            | [****] |

| 7.3   | Notwithstanding section 7.1, for any extra work not covered by this Service Agreement and agreed upon in writing between the Parties (the “Extra Work”), the Client shall pay to [****] the hourly rates and other fees indicated in this Appendix I attached hereto for the performance of the Services (The costs of the Services for the Extra Work and described in section 7.1 are collectively, the “Fees”). |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4   | Notwithstanding section 7.2 hereof, [****] will invoice the Client for the Extra Work, on a monthly basis for the Services that have been delivered or rendered by [****]. The Client shall pay [****] for these Services to the extent their performance has been pre-approved in writing by the Client. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.   | CONFIDENTIALITY |
|----------------|-----------------|

| 8.1   | Confidentiality issues are covered per the Non Disclosure Agreement and the MSA. |
|-----------------|----------------------------------------------------------------------------------|

| 9.   | REPRESENTATIONS AND WARRANTIES |
|----------------|--------------------------------|

| 9.1   | [****] hereby represents and warrants to the Client that: |
|-----------------|-----------------------------------------------------------|

| 9.1.1   | it is a duly organized and validly existing corporation under the laws of the jurisdiction in which it is incorporated; |
|-------------------|-------------------------------------------------------------------------------------------------------------------------|

| 9.1.2   | it has the necessary corporate power, authority, skills, and capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated hereby have been duly authorized. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2   | The Client hereby represents and warrants to [****] that: |
|-----------------|-----------------------------------------------------------|

| 9.2.1   | it is a duly organized and validly existing corporation under the laws of the jurisdiction in which it is incorporated; |
|-------------------|-------------------------------------------------------------------------------------------------------------------------|

| 9.2.2   | it has the necessary corporate power, authority, skills, and capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated hereby have been duly authorized; |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.   | TERMS AND CONDITIONS |
|-----------------|----------------------|

| 10.1   | This Service Agreement shall be governed, construed and interpreted according to the laws in force in the Province of Quebec and the applicable laws of Canada therein, and the courts of the legal district of Montreal, province of Quebec (Canada) shall have exclusive jurisdiction to hear any and all disputes arising hereunder. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2   | This Service Agreement is subject to the terms and conditions provided in the MSA and bind the parties as well as their respective successors, permitted assigns and legal representatives. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3   | This Service Agreement may be executed in counterparts, each of which shall be deemed to be an original and which together shall constitute one and the same agreement. This Service Agreement may also be executed between the Parties by exchange of facsimile transmissions or electronic transmissions in legible form, including without limitation in a tagged image format file (TIFF) or portable document format (PDF). |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.4   | The Parties hereto have requested that this Service Agreement be drafted in the English language.  Les Parties ont exigé que ce contrat de services soit rédigé en anglais. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| [****] Pharma Inc. |                      | 7810962 Canada Inc.                |
|--------------------|---------------------------|------------------------------------|
|               |                      |                               |
| Per:               | /s/                       |                               | Per: | /s/ Alain Guimond PhD |   |
| Name:              | [****]                    |                               | Name: Alain Guimond PhD |
| Title:             | VP Pharmaceutical R&D | Title: Senior Director of Research |

----

| Professional(Chemist or Engineer)                    | Hourly Rate*, **($USD) |
|------------------------------------------------------|------------------------|
| Senior scientist                                     | $240.00                |
| Scientist                                            | $200.00                |
| Technician                                           | $110.00                |
| R&D laboratory overhead( Equipment and supplies) | $ 75.00***             |

| Analyses                              | Cost / Sample *($USD) |
|--------------------------------------------|-----------------------|
| XRPD                                       | [****]                |
| SEM                                        | [****]                |
| TGA                                        | [****]                |
| DSC                                        | [****]                |
| Water Content (Karl Fisher)                | [****]                |
| Single point dissolution test/ vessel **** | [****]                |
| Assay****                                  | [****]                |
| Related Substances****                     | [****]                |
| Disintegration                             | [****]                |
| Hygroscopicity (5 conditions)              | [****]                |
| Solubility in water at pH 2, 4.5 and 7     | [****]                |
| Flow, Grinding and Compressibility         | [****]                |
| Particle Size and Distribution             | [****]                |
| Bulk and Tap Density                       | [****]                |
| Organoleptic (texture, color, appearance)  | [****]                |

| * | Prices can be changed by [****] without any prior notice. Prices apply only for non GMP work and analysis. GMP prices will be supplied on demand. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------|

| ** | All expenses will be charged at cost. |
|----|---------------------------------------|

| *** | Will be invoiced in addition to the professional fees when laboratory work is required. |
|-----|-----------------------------------------------------------------------------------------|

| **** | A set-up charge of $[****]/ HPLC method will be invoiced in addition to the sample cost. |
|------|------------------------------------------------------------------------------------------|

----